| Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes. | Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes.
Buchynskyi M, Oksenych V, Kamyshna I, Vorobets I, Halabitska I, Kamyshnyi O., Free PMC Article | 11/7/2024 |
| NR1H4 disease: rapidly progressing neonatal intrahepatic cholestasis and early death. | NR1H4 disease: rapidly progressing neonatal intrahepatic cholestasis and early death.
Li ZD, Li YC, Jing-Zhao, Wang JS, Xie XB., Free PMC Article | 04/29/2024 |
| Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation. | Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
Qin X, Tan Y, Ren W, Zhou W, Niu R, Liang L, Li J, Cao K, Wei G, Zhu X, Huang M. | 04/22/2024 |
| FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease. | FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease.
Li L, Kong L, Xu S, Wang C, Gu J, Luo H, Meng Q. | 02/20/2024 |
| Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease. | Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease.
Xu S, Kong L, Li L, Wang C, Gu J, Luo H, Meng Q. | 01/5/2024 |
| Farnesoid X receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease. | Farnesoid X receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease.
Jones BA, Myakala K, Guha M, Davidson S, Adapa S, Lopez Santiago I, Schaffer I, Yue Y, Allegood JC, Cowart LA, Wang XX, Rosenberg AZ, Levi M., Free PMC Article | 11/27/2023 |
| NR1H4-mediated circRHOBTB3 modulates the proliferation, metastasis, and Warburg effects of cervical cancer through interacting with IGF2BP3. | NR1H4-mediated circRHOBTB3 modulates the proliferation, metastasis, and Warburg effects of cervical cancer through interacting with IGF2BP3.
Ren A, Gong F, Liu G, Fan W. | 11/13/2023 |
| Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. | Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis.
Tschuck J, Theilacker L, Rothenaigner I, Weiß SAI, Akdogan B, Lam VT, Müller C, Graf R, Brandner S, Pütz C, Rieder T, Schmitt-Kopplin P, Vincendeau M, Zischka H, Schorpp K, Hadian K., Free PMC Article | 11/3/2023 |
| Farnesoid X receptor represses human sulfotransferase 1A3 expression through direct binding to the promoter. | Farnesoid X receptor represses human sulfotransferase 1A3 expression through direct binding to the promoter.
Dou Y, Pei S, Li Y, Wang M, Liu Z, Li J, Cao J, Qin J, Zhang M, Hou L, Sun H. | 10/30/2023 |
| Farnesoid X receptor enhances epithelial ACE2 expression and inhibits virally induced IL-6 secretion: implications for intestinal symptoms of SARS-CoV-2. | Farnesoid X receptor enhances epithelial ACE2 expression and inhibits virally induced IL-6 secretion: implications for intestinal symptoms of SARS-CoV-2.
Smyth JS, Truong JK, Rao A, Lin R, Foulke-Abel J, Adorini L, Donowitz M, Dawson PA, Keely SJ., Free PMC Article | 10/12/2023 |
| Regulon analysis identifies protective FXR and CREB5 in proximal tubules in early diabetic kidney disease. | Regulon analysis identifies protective FXR and CREB5 in proximal tubules in early diabetic kidney disease.
Shi W, Le W, Tang Q, Shi S, Shi J., Free PMC Article | 06/23/2023 |
| Differential Expression of FXR and Genes Involved in Inflammation and lipid Metabolism Indicate Adipose Tissue Dysfunction in Gestational Diabetes. | Differential Expression of FXR and Genes Involved in Inflammation and lipid Metabolism Indicate Adipose Tissue Dysfunction in Gestational Diabetes.
Valencia-Ortega J, González-Reynoso R, Salcedo-Vargas M, Díaz-Velázquez MF, Ramos-Martínez E, Ferreira-Hermosillo A, Mercado M, Saucedo R. | 04/24/2023 |
| The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases. | The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases.
Kim DH, Park JS, Choi HI, Kim CS, Bae EH, Ma SK, Kim SW., Free PMC Article | 03/7/2023 |
| The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. | The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.
Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA., Free PMC Article | 12/10/2022 |
| CEBPB regulates the bile acid receptor FXR to accelerate colon cancer progression by modulating aerobic glycolysis. | CEBPB regulates the bile acid receptor FXR to accelerate colon cancer progression by modulating aerobic glycolysis.
Wang Z, Pang J, Wang L, Dong Q, Jin D., Free PMC Article | 12/3/2022 |
| Transcription Factor FXR Activates DHRS9 to Inhibit the Cell Oxidative Phosphorylation and Suppress Colon Cancer Progression. | Transcription Factor FXR Activates DHRS9 to Inhibit the Cell Oxidative Phosphorylation and Suppress Colon Cancer Progression.
Zhao J, Wang Y, Wang Y, Gao J, Yang H, Wu X, Li H., Free PMC Article | 11/19/2022 |
| A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARalpha) and farnesoid X receptor (FXR). | A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. | 10/1/2022 |
| Reduced peroxisome proliferator-activated receptor-alpha and bile acid nuclear receptor NR1H4/FXR may affect the hepatic immune microenvironment of biliary atresia. | Reduced peroxisome proliferator-activated receptor-α and bile acid nuclear receptor NR1H4/FXR may affect the hepatic immune microenvironment of biliary atresia.
Ma Y, Lu L, Tan K, Li Z, Guo T, Wu Y, Wu W, Zheng L, Fan F, Mo J, Gong Z., Free PMC Article | 10/1/2022 |
| Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes. | Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes.
Kim DH, Choi HI, Park JS, Kim CS, Bae EH, Ma SK, Kim SW., Free PMC Article | 07/16/2022 |
| Identification of two novel pathogenic variants of the NR1H4 gene in intrahepatic cholestasis of pregnancy patients. | Identification of two novel pathogenic variants of the NR1H4 gene in intrahepatic cholestasis of pregnancy patients.
Lai H, Liu X, Xin S, Zheng J, Liu H, Ouyang Y, Yang H, Zeng Y, Zou Y, Zeng X., Free PMC Article | 06/18/2022 |
| Farnesoid X receptor functions in cervical cancer via the p14(ARF)-mouse double minute 2-p53 pathway. | Farnesoid X receptor functions in cervical cancer via the p14(ARF)-mouse double minute 2-p53 pathway.
Huang X, Wang B, Shen H, Huang D, Shi G., Free PMC Article | 06/18/2022 |
| Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers. | Enhancement of Farnesoid X Receptor Inhibits Migration, Adhesion and Angiogenesis through Proteasome Degradation and VEGF Reduction in Bladder Cancers.
Lai CR, Wang HH, Chang HH, Tsai YL, Tsai WC, Lee CR, Changchien CY, Cheng YC, Wu ST, Chen Y., Free PMC Article | 05/21/2022 |
| Pleiotropic roles of FXR in liver and colorectal cancers. | Pleiotropic roles of FXR in liver and colorectal cancers.
Huang X, Fan M, Huang W., Free PMC Article | 04/23/2022 |
| FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption.
Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlström A, Ashby JW, Barshop W, Wohlschlegel J, Calkin AC, Liu Y, Thorell A, Meikle PJ, Drew BG, Mack JJ, Marschall HU, Tarling EJ, Edwards PA, de Aguiar Vallim TQ., Free PMC Article | 04/16/2022 |
| Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W, Fan W, Tang T, Wan H, Zhao S, Tan Y, Oware KA, Tan J, Li J, Qu S., Free PMC Article | 03/26/2022 |